- Home
- SWIN vs FGEN Comparison
SWIN vs FGEN Comparison
Compare SWIN & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- FGEN
- Stock Information
- Founded
- SWIN 2017
- FGEN 1993
- Country
- SWIN Hong Kong
- FGEN United States
- Employees
- SWIN N/A
- FGEN N/A
- Industry
- SWIN
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- FGEN Health Care
- Exchange
- SWIN Nasdaq
- FGEN Nasdaq
- Market Cap
- SWIN 32.1M
- FGEN 33.5M
- IPO Year
- SWIN 2023
- FGEN 2014
- Fundamental
- Price
- SWIN $3.00
- FGEN $7.43
- Analyst Decision
- SWIN
- FGEN Strong Buy
- Analyst Count
- SWIN 0
- FGEN 1
- Target Price
- SWIN N/A
- FGEN $250.00
- AVG Volume (30 Days)
- SWIN 268.8K
- FGEN 72.2K
- Earning Date
- SWIN 08-21-2025
- FGEN 08-05-2025
- Dividend Yield
- SWIN N/A
- FGEN N/A
- EPS Growth
- SWIN N/A
- FGEN N/A
- EPS
- SWIN N/A
- FGEN N/A
- Revenue
- SWIN $3,316,000.00
- FGEN $6,996,000.00
- Revenue This Year
- SWIN $29.79
- FGEN N/A
- Revenue Next Year
- SWIN $54.60
- FGEN N/A
- P/E Ratio
- SWIN N/A
- FGEN N/A
- Revenue Growth
- SWIN N/A
- FGEN N/A
- 52 Week Low
- SWIN $1.16
- FGEN $4.50
- 52 Week High
- SWIN $4.40
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- SWIN 60.43
- FGEN 61.84
- Support Level
- SWIN $2.88
- FGEN $5.37
- Resistance Level
- SWIN $4.40
- FGEN $5.73
- Average True Range (ATR)
- SWIN 0.46
- FGEN 0.50
- MACD
- SWIN 0.06
- FGEN 0.21
- Stochastic Oscillator
- SWIN 57.08
- FGEN 87.87
About SWIN Solowin Holdings
Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.